Closed article
A cartridge-centered workflow intended to keep the embryo within one controlled article across loading, bounded hold or transport, and at least early recovery.
Investor-facing public overview
Closed, embryo-specific biopreservation workflows for high-value reproductive medicine.
Kura Biopreservation is developing a professional-use cartridge workflow intended to reduce handling burden, preserve chain of custody, and support bounded non-cryogenic preservation-state maintenance with staged recovery.
This website provides a general company overview and is not an offer to sell, or a solicitation of an offer to buy, securities. Offering materials, financial terms, projections, and technical diligence materials are available only through company-approved channels and appropriate access controls.
Problem / Solution
The workflow problem is bigger than storage alone.
Embryo preservation touches handling, witnessing, custody, transport, recovery, and documentation. Kura’s first wedge is a closed cartridge workflow designed to simplify a defined professional-use episode while protecting the confidential details that support the underlying technology.
Embryo-specific design
Architecture centered on embryo localization, gentle support, controlled exchange, identity support, and staged recovery rather than generic cell-storage positioning.
Milestone-driven proof
Seed-stage value creation is organized around prototypes, exchange and hold behavior, staged recovery workflow, and early biology signals.
Kura Wedge A
Load → seal → hold → staged recovery.
A bounded professional-use cartridge episode gives investors and strategic partners a clear first product logic while preserving confidential technical implementation details.
1
Load
Professional embryology handling into an embryo-specific cartridge environment.
2
Seal
Closed or substantially closed configuration with identity and custody support.
3
Hold
Defined non-cryogenic preservation-state maintenance under a controlled envelope.
4
Recover
Staged rehydration or recovery logic designed to avoid abrupt return conditions.
5
Return
Transition back to a usable embryology workflow after qualification gates.
Market Lens
Premium disposable cartridge logic, not commodity consumables.
Kura’s commercial thesis is that a narrow first article can justify premium economics if it reduces handling burden, custody friction, transport disruption, and recovery complexity in high-value workflows.
Commercial model
The public overview focuses on company positioning, workflow value, and controlled investor access. Detailed use of funds, pricing models, market assumptions, financing terms, and risk factors are handled through private investor materials.
Disposable cartridge episode
Professional-use workflow
Future reader/services layers
Licensing optionality
Traction / Milestones
Visible proof beats platform hype.
Kura’s roadmap emphasizes engineering and validation milestones while keeping protocols, formulation recipes, operating windows, and device dimensions outside the public website.
Design freeze
Prototype plan, supplier path, and test architecture.
Benchtop data
Geometry, exchange, sealing, and workflow behavior.
Hold envelope
Controlled environment and staged recovery workflow.
Biology signal
Early embryo-model readouts and recovery qualification.
Pilot package
Data room, SOPs, KOL feedback, and next-round readiness.
IP & License
Fareban Holdings owns the platform IP; Kura commercializes through a licensed operating-company model.
Kura Biopreservation is an operating company of Fareban Holdings. Its defined commercialization activities are supported by exclusive field rights licensed from Fareban Holdings, the IP-owning HoldCo. Fareban Holdings is online at www.farebanholdings.com.
Patent-protective public posture
Kura describes its product architecture, workflow value, corporate relationship, and milestone logic at a high level. Enabling formulations, state-window parameters, cargo designs, microgeometry dimensions, and stepwise operating conditions are reserved for controlled diligence and protected technical files.
Team
Built for disciplined execution.
Kura combines founder-led IP origination with scientific, clinical, corporate, and legal support across embryo handling, bioengineering, quality systems, licensing, financing controls, and investor diligence.
Founder / Inventor
Kenneth Frimpong — company formation, IP origination, strategy, and investor engagement.
Scientific & Clinical Advisors
Embryology, IVF laboratory workflow, bioengineering, quality systems, and translational validation advisors.
Corporate & Legal
Fareban Holdings governance, license management, financing controls, securities compliance, and data-room process.
Investor Notice
Important legal and regulatory notices.
Kura provides this public overview for general corporate information, qualified investor introductions, and strategic-partner awareness.
No securities offer
This website is for general informational purposes only and is not an offer to sell, or a solicitation of an offer to buy, securities. Any offering, if made, will be made only through definitive offering documents and in compliance with applicable law.
No public investment terms
No person may invest based on this website. Financing terms, valuation, projections, risk factors, subscription materials, and investor eligibility procedures are not provided on this public page.
Forward-looking statements
Statements about plans, milestones, development paths, regulatory strategy, markets, product performance, and commercialization are forward-looking and subject to scientific, regulatory, financing, operational, IP, and market risks.
Regulatory status
Kura’s product candidates are in development and are not represented as approved, cleared, validated, or commercially available for clinical use. No clinical outcome, superiority, replacement, or safety claim is made.
Confidential diligence
Detailed technical materials, patents, protocols, formulations, microgeometry dimensions, datasets, and commercial assumptions are provided only through controlled diligence channels.
Qualified inquiries only
Investor communications may require verification of investor status, suitability, jurisdiction, relationship history, and other compliance factors before any financing discussion or private scheduling link is provided.
Investor and strategic-partner inquiries start with written intake.
Kura Biopreservation uses the same all-company investor intake standard as the broader portfolio process. Investor inquiries, optional requests for investor materials, and strategic-partner introductions are reviewed before any confidential materials or private scheduling links are shared. Investor inquiries may be directed to investors@kurastasis.com; general inquiries to inquiries@kurastasis.com; and strategic partnership inquiries to partnerships@kurastasis.com.
Investor relationsinvestors@kurastasis.com
General inquiriesinquiries@kurastasis.com
Strategic partnershipspartnerships@kurastasis.com
Official websitewww.kurastasis.com
No Public Scheduling LinkPlease submit an inquiry first. Qualified inquiries may receive private meeting options after review.